CDMO
Revolutionary CDMO Wheeler Bio Appoints Patrick Lucy as CEO
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-24-CL-08Oct 11, 2024
Leap-In Transposase
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Wheeler Bio
PAO-06-24-CL-05May 30, 2024
The PHASE Platform
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success
Wheeler Bio
PAO-05-24-CL-01May 08, 2024
Portable CMC
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
Wheeler Bio
PR-M02-29-01Feb 29, 2024
CMC
Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform
Wheeler Bio
PAO-12-23-CL-04Feb 08, 2024
Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC
Wheeler Bio
PR-M11-23-01Nov 08, 2023
Wheeler Bio Announces Grand Opening of Biomanufacturing Facility
Wheeler Bio
PR-M10-23-01Oct 05, 2023
Business Leadership
Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer
Wheeler Bio
PR-M08-23-01Aug 15, 2023
CMC
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.
Wheeler Bio
PAO-07-23-CL-05Jul 26, 2023
Leadership
Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer
Wheeler Bio
PR-M06-23-02Jun 06, 2023
Series A Funding
Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma
Wheeler Bio
PR-M10-22-02Oct 05, 2022
Cell Line Development
Integrating Cell Line and CMC Development
Stephen Hamilton, Ph.D.; Mike Brem
Wheeler Bio
PAO-06-022-CL-12Sep 02, 2022
Financing
Wheeler Bio Announces $14M Seed Round To Expand Access To Portable CMC™
Wheeler Bio
PR-M01-22-01Jan 04, 2022